Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) Stock Quotes and News

Salix Pharmaceuticals, Ltd. (SLXP) 0.00 -0.53

Price Open:	59.26	Day's Range:	0.00000 - 60.12000
Price Close:	59.28	52wk Range:	0.00000 - 60.12000
Price Day Change:	-0.53	Volume:	474,997
Price % Change:	-0.89	Market Cap:	3.602B
Bid:	0.00000	PE Ratio:	48.75
Ask:	0.00000	EPS Diluted:	1.216

Trade SLXP NOW!

The Latest On SLXP

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash 3/21/13 6:54am

Top 4 Stocks In The Drugs-Generic Industry With The Highest Profit Margin 3/15/13 4:56am

UPDATE: Bank of America Raises PT on Salix Pharmaceuticals on Sales Estimates 3/13/13 12:19pm

UPDATE: Bank of America Raises PT on Salix Pharmaceuticals on Pipeline Credit 3/13/13 10:26am

UPDATE: Cantor Fitzgerald Raises PT on Salix Pharmaceuticals on In-Line 4Q12 Results 3/1/13 1:39pm

If The Market Falls, Try These Low Beta ETFs 2/28/13 7:27pm

Benzinga's Top Initiations 1/31/13 8:59am

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Cash 1/7/13 4:17am

Cantor Fitzgerald Reiterates Buy Rating, $60 PT on Salix Pharmaceuticals Ltd. 1/2/13 2:57pm

US Stock Futures Higher On Fiscal-Cliff Deal 1/2/13 8:13am

FDA Approves Fulyzaq 125 mg Delayed-Release Tablets for Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy 1/2/13 8:07am

Stocks To Watch For January 2, 2013 1/2/13 2:44am

Press Releases

Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013 5/17/13 Business Wire

Salix Pharmaceuticals Reports 1Q2013 Results 5/9/13 Business Wire

Salix Pharmaceuticals to Present at BofA Merrill Lynch 2013 Health Care Conference 5/7/13 Business Wire

Salix Pharmaceuticals Announces 1Q2013 Financial Results Conference Call and Webcast 4/25/13 Business Wire

Salix Pharmaceuticals Reports 4Q2012 and FY2012 Results 2/28/13 Business Wire

Salix Pharmaceuticals to Present at Two Investment Conferences in March 2/25/13 Business Wire

Salix Pharmaceuticals Announces 4Q2012 and FY2012 Financial Results Conference Call and Webcast 2/14/13 Business Wire

FDA Approves Fulyzaq™ (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART) 1/2/13 Business Wire

Salix Pharmaceuticals to Present at J.P. Morgan Healthcare Conference 1/2/13 Business Wire

Get the latest SLXP stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Salix Pharmaceuticals, Ltd. stock price.

Partner Headlines

FDA Accepts Actavis NDA - Analyst Blog 5/20/13

Good News for Roche's Tarceva - Analyst Blog 5/16/13

Good News for Novartis' Ilaris - Analyst Blog 5/15/13

FDA Accepts Merck BLA - Analyst Blog 5/15/13

Salix Beats on Earnings - Analyst Blog 5/14/13

Santarus to Make Cash Milestone Payment - Analyst Blog 4/18/13

Santarus' Uceris Data Published - Analyst Blog 3/20/13

Salix Misses on Both Counts - Analyst Blog 3/5/13

Earnings Beat at Endo Health - Analyst Blog 3/4/13

Valeant Misses 4Q Estimates - Analyst Blog 3/1/13

Impax Beats on Both Counts - Analyst Blog 3/1/13